DOBUTAMINE-HAMELN (Hameln Pharma Pty Ltd)
Product name
DOBUTAMINE-HAMELN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
144 (255 working days)
Active ingredients
dobutamine hydrochloride
Registration type
New generic medicine
Indication
Dobutamine-hameln is indicated in adults who require short-term treatment of cardiac failure secondary to acute myocardial infarction, or cardiac surgery.